Sodium adenozintrifosfata-Darnitsa

General characteristics. Structure:

Active ingredient: adenosintriphosphate sodium, adenosine-5 '-trifosfornoy acids disodium salt three-water;

1 ml of solution for injections contains ATP of disodium salt (adenosine of triphosphate of disodium salt) in terms of 100% anhydrous substance of 10 mg;

excipients: sodium hydroxide (2 M solution), water for injections.

Pharmacological properties:

Pharmacodynamics. Adenosinetriphosphate (ATP) is natural makroergichesky connection. It is synthesized practically in all body tissues by oxidizing phosphorylation and in the course of splitting of carbohydrates. It is most of all synthesized in muscular tissue where the energy concluded in molecules ATP is used at muscular contraction. The energy released at ATP disintegration is used in synthesis processes, in particular a squirrel, urea.

In a nervous system of molecule ATP carry out a neurotransmitter role, transmit a signal in purinergichesky synapses. At the same time ATP accompanies atsetilkholinovy and noradrenergichesky mediation.

At system administration of Sodium adenozintrifosfat-Darnitsa shows metabolic, antiarrhytmic action, improves cerebral and coronary circulation. Antiarrhytmic action is connected with suppression of automatism of a sinus node and carrying out impulses on Purkinye's fibers.

Partially blocks calcium channels and facilitates transmembrane movement of potassium ions.

Pharmacokinetics. It is not possible to trace kinetics of parenterally administered drug ATP because of the high voltage of the various reactions happening to participation of own ATP. At the same time it is known that sodium adenosinetriphosphate quickly breaks up on site introductions to adenosine and the phosphatic remains which are used further for synthesis of new molecules ATP.

Pharmaceutical characteristics.

Main physical and chemical properties: transparent colourless or slightly yellowish liquid.

Incompatibility. The drug cannot be administered along with carbamazepine, Dipiridamolum, xanthines, antiarrhytmic means.

Indications to use:

As a part of complex therapy of muscular dystrophy and an atrophy; for stopping of paroxysms of supraventricular tachycardia; at spasms of peripheral vessels (the alternating lameness, a Raynaud's disease, an obliterating thromboangitis).

At the central, peripheral and mixed forms of a hereditary pigmental degeneration of a retina.

Route of administration and doses:

Sodium adenozintrifosfat-Darnitsa enter intramusculary or intravenously.

For treatment of muscular dystrophies, disturbances of peripheric circulation in the first 2-3 days appoint 1 ml intramusculary once a day, in the next days – on 1 ml 2 times a day or at once 2 ml once a day. A course of treatment – 30-40 days. If necessary the course is repeated in 1-2 months.

At a hereditary pigmental degeneration of a retina enter 5 ml intramusculary   2 times a day, with an interval of 6-8 hours, daily within 15 days. If necessary courses can be repeated with an interval of 8-12 months.

For stopping of supraventricular tachyarrhythmias enter intravenously 1-2 ml within  5-10 seconds (the effect is observed in 20-40 seconds). If necessary repeatedly enter the same dose in 2-3 minutes.

Features of use:

Use during pregnancy or feeding by a breast.

The uses of drug given relatively during pregnancy and feeding by a breast are absent.

Children.

Experience of use of drug to children is absent therefore drug is contraindicated to this age category.

Special security measures.

Intravenous administration of drug, as a rule, needs to be carried out in the conditions of a hospital, under medical observation, at control of function of heart, slowly, then it is desirable to measure arterial pressure.

It is careful to apply at the expressed bradycardia, a sick sinus syndrome, AV-blockade І degrees, tendencies to arterial hypotension.

The drug cannot be administered in high doses along with cardiac glycosides.

Ability to influence speed of response at control of motor transport or work with other mechanisms.

During treatment it is necessary to refrain from control of motor transport or work with other mechanisms requiring special attention.

Side effects:

From the central nervous system: a headache, dizziness, a short-term loss of consciousness, feeling of compression in the head, a phobia.

From an organ of sight: sight illegibility.

From digestive tract: nausea, metal smack in a mouth, strengthening of motility of digestive tract (at intravenous administration).

From cardiovascular system: a heart consciousness, a sensation of discomfort in a thorax, tachycardia or bradycardia, arterial hypotension, arrhythmia, AV conductivity disturbance (atrioventricular block), an asystolia.

From a musculoskeletal system: hand, spin, neck pain.

From an urinary system: strengthening of a diuresis.

From respiratory system: asthma, bronchospasm.

Changes from skin and hypodermic cellulose: a hyperemia of the person, an itch, rash on skin.

Disturbances in an injection site: feeling of a pricking.

Allergic reactions: hypersensitivity reactions, allergic dermatitis, small tortoiseshell, acute anaphylaxis.

General frustration: the increased sweating, a hyperthermia, feeling of heat.

Interaction with other medicines:

At combined use with Dipiridamolum action of Dipiridamolum, in particular vasodilating effect amplifies.

Some antagonism at combined use of drug with purine derivatives (caffeine and theophylline) is shown.

It is impossible to enter along with cardiac glycosides in high doses as the risk of development of side reactions from cardiovascular system amplifies.

At simultaneous use with Xantinoli nicotinas the effect of sodium of adenosinetriphosphate decreases.

Carbamazepine can strengthen effects of adenosine, lead to blockade development.

Contraindications:

Individual hypersensitivity to drug, an acute myocardial infarction, arterial hypotension, severe forms of bradyarrhythmias, AV blockade of the II-III degree, a dekompensirovanny stage of heart failure, cardiogenic shock and other types of shocks, QT prolongation syndrome, a hemorrhagic stroke; inflammatory diseases of lungs, chronic obstructive diseases of lungs (for example, bronchial asthma); pregnancy, feeding period breast, children's age. It is impossible to enter along with cardiac glycosides in high doses.

Overdose:

Symptoms: dizziness, arterial hypotension, short-term loss of consciousness, arrhythmia, atrioventricular block of II and III degrees, asystolia, bronchospasm, ventricular disturbances, sinus bradycardia and tachycardia. Development of allergic reactions is also possible.

Treatment. Administration of drug is immediately stopped and appoint cardiotonic means. Therapy is symptomatic. Competitive antagonists of adenosine are xanthines (an Euphyllinum, theophylline).

Storage conditions:

Period of validity. 2 years. To store in original packaging at a temperature from 2 °C to 8 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 1 ml in an ampoule; on 10 ampoules in a box; on 5 ampoules in a blister strip packaging; on the 2nd blister strip packagings in a pack.